| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/03/2003 | WO2002010387A3 G-protein coupled receptors |
| 01/03/2003 | WO2002009761A3 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2001098512A3 Control of metabolism with compositions of the human 2-oxoglutarate carrier |
| 01/03/2003 | WO2001098331A3 Glucagon-like peptide-1 analogs |
| 01/03/2003 | WO2001081408A9 G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same |
| 01/03/2003 | WO2001064899A8 Nucleotide sequences encoding proteins that take part in the biosynthesis of l-serine, improved method for microbially producing l-serine, and genetically modified microorganism suitable for use in said method |
| 01/03/2003 | WO2001044260A8 Novel purines |
| 01/03/2003 | CA2459985A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2455300A1 Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| 01/03/2003 | CA2455292A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2455288A1 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/03/2003 | CA2451839A1 Pharmaceutical compositions comprising peptides and permeation enhancers |
| 01/03/2003 | CA2451271A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2451250A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | CA2451249A1 Amino nicotinate derivatives as glucokinase (glk) modulators |
| 01/03/2003 | CA2451146A1 Method for manufacturing of free-flowing powder containing water-dispersible sterols |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450947A1 Black soybean polysaccharides |
| 01/03/2003 | CA2450925A1 G-protein coupled receptors |
| 01/03/2003 | CA2450762A1 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450550A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | CA2450491A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450174A1 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 01/03/2003 | CA2450001A1 Stable pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449998A1 Stable controlled release pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449990A1 Type 1 diabetes diagnostics and therapeutics |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | CA2449441A1 3-fluoro-pyrrolidines as antidiabetic agents |
| 01/03/2003 | CA2449439A1 Particles for inhalation having rapid release properties |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004341 Antidiabetic agents and dietetics |
| 01/02/2003 | US20030004215 Oral administering alpha-hydroxycarboxylic acid |
| 01/02/2003 | US20030004212 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists |
| 01/02/2003 | US20030004211 Carbohydrate modifying agent and drinks containing the modifying agent |
| 01/02/2003 | US20030004196 Antiinflamamtory agents; autoimmune disease |
| 01/02/2003 | US20030004194 Method for treating fibrotic diseases or other indications VI |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004169 Modulators of dopamine neurotransmission |
| 01/02/2003 | US20030004166 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004162 Antidiabetic agents; dietetics |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004156 Anticholesterol agents; cardiovascular disorders; antidiabetic agents; antiproliferative agents |
| 01/02/2003 | US20030004153 Novel heteroaryl-diazabicycloalkanes |
| 01/02/2003 | US20030004144 Anticancer agents; skin disorders |
| 01/02/2003 | US20030004139 Antidiabetic agents |
| 01/02/2003 | US20030004138 Hypoglycemic agents; antidiabetic agents; dietetics |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004135 Composition and method for the treatment of dysglucaemia |
| 01/02/2003 | US20030004129 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004115 Pharmaceutical preparation and method for treatment of diabetes |
| 01/02/2003 | US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 01/02/2003 | US20030004099 The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030004096 Polypeptide mixture containing preservative, surfactant and stabilizer |
| 01/02/2003 | US20030003516 Therapeutic and diagnostic uses of antibody specificity profiles |
| 01/02/2003 | US20030003131 Method for manufacture of free-flowing powder containing water-dispersible sterols |
| 01/02/2003 | US20030003120 A phenolic fraction of fruit obtained from the Rosaceae family, including at least 10% by weight of the sum of phloridzin, chlorogenic acid, epicatechin, quercitrin, procyanidin B2, p-coumaric acid and caffeic acid |
| 01/02/2003 | US20030003099 Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | EP1270585A1 Peptide derivative |
| 01/02/2003 | EP1270584A1 Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| 01/02/2003 | EP1270577A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270562A2 Cyclic alpha-amino-gamma-hydroxy-amides, process for their preparation and pharmaceutical compositions thereof |
| 01/02/2003 | EP1270558A1 "Compound for the treatment of atherosclerotic-thrombotic pathological conditions" |
| 01/02/2003 | EP1270032A1 Device for parenterally delivering solid drug compositions |
| 01/02/2003 | EP1270012A1 Use of pulmonary administration of insulin for treatment of diabetes |
| 01/02/2003 | EP1270011A1 Drugs for ameliorating impaired glucose tolerance |
| 01/02/2003 | EP1270004A1 Diuretics containing gamma-tocotrienol |
| 01/02/2003 | EP1270001A1 Pharmaceutical composition containing calcium acetate and calcium carbonate |
| 01/02/2003 | EP1269198A2 Identification of mast/basophil activation inhibitors |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1269191A1 Docosahexaenoic acid as retinoid x receptor and uses thereof |
| 01/02/2003 | EP1268835A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268793A2 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268775A1 The high bone mass gene of 11q13.3 |
| 01/02/2003 | EP1268768A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/02/2003 | EP1268753A2 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 01/02/2003 | EP1268559A1 Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation |
| 01/02/2003 | EP1268558A1 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 01/02/2003 | EP1268544A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 01/02/2003 | EP1268540A2 Proteins amf-1 to amf-10 and nucleic acids encoding same |
| 01/02/2003 | EP1268518A1 Insulin potentiating peptides |
| 01/02/2003 | EP1268503A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 01/02/2003 | EP1268502A1 O-aryl glucoside sglt2 inhibitors and method |
| 01/02/2003 | EP1268498A1 Cardioprotective phosphonates and malonates |
| 01/02/2003 | EP1268495A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268494A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268489A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268484A1 Condensed imidazoles as histamine h3 receptor ligands |